Parsons Wins $24 Million Biodefense Research Contract
CHANTILLY, Va. — Parsons Corporation (NYSE: PSN) has announced the awarding of a significant contract focused on biological defense research to aid the Naval Medical Research Command (NMRC) in managing the risks posed by biological and chemical warfare threats. This contract is valued at $24 million and includes a one-year base period with four optional one-year extensions.
Enhancing National Security Through Research
As part of this contract, Parsons will bolster support for NMRC’s Biological Defense Research Directorate (BDRD). This partnership aims to further biological research that enables quick detection of infectious diseases critical to the Department of Defense's operations. The focus on enhancing global disease surveillance will also be vital for early pathogen detection and timely responses, ensuring military personnel remain safe and healthy.
Biodiversity Research Expertise
“Our team of world-class scientists at Parsons, in conjunction with our leading biodefense capabilities, plays a crucial role in the federal government’s efforts to combat biological threats,” said Jon Moretta, President of Engineered Systems at Parsons. “We are eager to continue this vital work with the Naval Medical Research Command, protecting U.S. military personnel stationed globally.”
Since 2018, Parsons has been committed to providing experts in various fields including molecular biology, immunology, serology, and bacteriology, among others, to the NMRC. The services provided under this contract encompass a comprehensive range of biodefense solutions, from risk assessments and biological threat detection to incident response management.
Parsons' Commitment to Biodefense
Parsons offers a full suite of biodefense services, including biological threat identification, surveillance measures, and technical expertise addressing biosecurity issues. As bio-threats continue to evolve, Parsons is dedicated to ensuring preparedness and effective responses, underscoring the importance of their ongoing work with the NMRC.
Company Overview and Contact Information
Parsons (NYSE: PSN) stands at the forefront of disruptive technology provision in the national security and global infrastructure sectors. The company excels in various domains, including cyber intelligence, missile defense, urban development, and environmental remediation. To explore Parsons' biodefense offerings and overall capabilities, interested parties can visit their official website.
For those looking to reach out for more information or inquiries regarding this contract, the following contacts are available:
Media Contact:
Jonathan Larry
+1 706.832.7330
jonathan.larry@parsons.com
Investor Relations Contact:
Dave Spille
+1 703.775.6191
Dave.Spille@parsons.us
Frequently Asked Questions
What is the value of the recent contract awarded to Parsons?
The contract awarded to Parsons is valued at $24 million.
What is the primary focus of Parsons' contract with the NMRC?
The contract focuses on advancing biodefense research and supporting the rapid detection of infectious diseases.
Since when has Parsons been working with the NMRC?
Parsons has been supporting the NMRC since 2018.
What kind of research expertise does Parsons provide?
Parsons provides expertise in molecular biology, immunology, serology, and bacteriology, among other fields.
How can stakeholders learn more about Parsons' work?
Stakeholders can visit Parsons' official website for detailed information about their biodefense solutions and capabilities.
